Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | MLNR | O43193 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.37 |
| ▸ | MCOLN1 | Q9GZU1 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310923 | 0.88 | PTGDR2 (0.40) | PTGDR2MLNRBRD4ALDH1A1LMNA | |
| SCHEMBL3311146 | 0.86 | PTGDR2 (0.39) | PTGDR2MLNRBRD4ALDH1A1LMNA | |
| SCHEMBL3310627 | 0.85 | PTGDR2 (0.38) | PTGDR2MLNRBRD4POLBALDH1A1 | |
| SCHEMBL3310872 | 0.83 | GAA (0.40) | POLBLMNATP53MAPTSMN1; SMN2 | |
| SCHEMBL3317889 | 0.82 | CHRM1 (0.42) | POLBALDH1A1LMNAKDM4ETP53 | |
| SCHEMBL3312048 | 0.80 | ALDH1A1 (0.44) | PTGDR2ALDH1A1LMNAKDM4EMAPT | |
| SCHEMBL3314883 | 0.79 | PTGDR2 (0.42) | PTGDR2BRD4POLBALDH1A1HTR6 | |
| SCHEMBL3314408 | 0.79 | ALDH1A1 (0.41) | ALDH1A1KDM4EMAPTSMN1; SMN2GAA | |
| SCHEMBL3311243 | 0.79 | KMT2A (0.40) | BRD4POLBALDH1A1LMNAKDM4E | |
| SCHEMBL3312719 | 0.78 | DRD2 (0.38) | PTGDR2LMNAMAPTSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113502-A1 | Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | US | claimed |
| EP-1863810-A1 | NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1' RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | claimed |
| WO-2006101434-A1 | NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2006-09-28 | — | — | WO | claimed |
| US-20100113502-A1 | Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | US | disclosed |
| EP-1863810-A1 | NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1' RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006101434-A1 | NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113502-A1 | Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands | CNR1, CNR2, OPRL1 | PTGDR2 93/4885MLNR 441/4885BRD4 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.